查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
亞太地區下一代乳癌診斷與篩檢市場：分析與預測（2023-2032）
市場調查報告書
商品編碼
1439030

亞太地區下一代乳癌診斷與篩檢市場：分析與預測（2023-2032）

Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market: Analysis and Forecast, 2023-2032
出版日期: | 出版商: BIS Research | 英文 82 Pages | 商品交期: 1-5個工作天內

價格

亞太地區下一代乳癌診斷和篩檢市場規模預計將從2023年的5.543億美元成長到2032年的17.794億美元。

亞太地區下一代乳癌診斷與篩檢市場：簡介

主要市場統計數據
預測期 2023-2032
2023年評估 5.543 億美元
2032年預測 17.794 億美元
複合年成長率 13.84%

預計亞太地區下一代乳癌診斷和篩檢市場將顯著成長。這一成長是由該地區乳癌發病率上升等因素推動的。活性化以早期檢測和篩檢為重點的宣傳宣傳活動也促成了這一激增。此外，人們越來越重視利用乳癌生物標記進行更有效的篩檢、預後預測和個人化治療策略。此外，市場相關人員之間的協作努力和夥伴關係進一步支持診斷技術和篩檢方法的進步。在此背景下，亞太地區下一代乳癌診斷和篩檢市場為改善全部區域的乳癌管理和結果提供了一個充滿希望的機會。

本報告調查了亞太地區下一代乳癌診斷和篩檢市場，提供了市場概況、技術趨勢、法律制度、市場影響因素分析、市場規模趨勢和預測、競爭形勢和分析。主要企業等進行了總結。

市場分類

細分 1：按國家/地區

  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 新加坡
  • 其他

目錄

執行摘要

調查範圍

第1章 腫瘤分子診斷市場

  • 概述
  • 癌症類型
  • 科技
  • 市場動態
  • 監管部門核准的產品

第2章下一代乳癌診斷與篩檢市場

  • 市場展望
    • 產品定義
    • 定義：透過相關技術
    • 包容與排除
    • 概述

第3章 產業展望

  • 主要趨勢
    • 液態切片用於乳癌診斷
    • 下一代技術的全自動化
  • 法律規範
    • 美國法規結構
    • 歐洲法規結構
    • 亞太法規結構
  • 監管部門核准的產品
  • 臨床試驗
  • 乳癌發生率增加（按國家/地區）
  • 不同技術的優點和局限性
  • 價錢

第4章 區域

  • 亞太地區
    • 主要發現
    • 市場動態
    • 市場規模/預測

第5章市場：競爭基準化分析

  • 下一代乳癌診斷和篩檢活躍的公司生態系統
  • 公司簡介
    • BGI Genomics Co., Ltd.
Product Code: BHP1877SS

The Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Expected to Reach $1,779.4 Million by 2032

Introduction to Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market

KEY MARKET STATISTICS
Forecast Period2023 - 2032
2023 Evaluation$554.3 Million
2032 Forecast$1,779.4 Million
CAGR13.84%

The Asia-Pacific next-generation breast cancer diagnostic and screening market was valued at $554.3 million in 2023 and is anticipated to reach $1,779.4 million by 2032. The anticipated growth in the next-generation breast cancer diagnostic and screening market is projected to be fueled by several factors. These include the uptick in the occurrence of breast cancer cases, heightened awareness concerning early detection of breast cancer, a growing emphasis on breast cancer biomarkers for improved screening, prognosis, and tailored treatment, as well as the escalation in partnerships and collaborations among industry participants.

Market Introduction

The Asia-Pacific (APAC) region anticipates significant growth in the next-generation breast cancer diagnostic and screening market. This growth is propelled by various factors, including the increasing incidence of breast cancer cases in the region. Heightened awareness campaigns focusing on early detection and screening contribute to this surge. Additionally, there's a growing emphasis on utilizing breast cancer biomarkers for more effective screening, prognosis, and personalized treatment strategies. Moreover, the collaborative efforts and partnerships among market players further drive advancements in diagnostic technologies and screening methodologies. With these dynamics in play, the APAC next-generation breast cancer diagnostic and screening market presents promising opportunities for improved breast cancer management and outcomes across the region.

Market Segmentation

Segmentation 1: by Country

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest-of-Asia-Pacific

How can this report add value to an organization?

Growth/Marketing Strategy: The APAC next-generation breast cancer diagnostic and screening market has seen major development by key players operating in the market, such as business expansions, partnerships, collaborations, mergers and acquisitions, product launches, and funding activities. Partnerships, alliances, and business expansions accounted for the maximum number of key developments in the APAC next-generation breast cancer diagnostic and screening market, followed by regulatory and legal activities and mergers and acquisitions.

Competitive Strategy: Key players in the APAC next-generation breast cancer diagnostic and screening market analyzed and profiled in the study involve players that offer next-generation breast cancer diagnostic and screening products and services. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, product launches and approvals, and funding scenarios will aid the reader in understanding the untapped revenue pockets in the market.

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1 Oncology Molecular Diagnostic Market

  • 1.1 Overview
  • 1.2 Cancer Type
  • 1.3 Technology
  • 1.4 Market Dynamics
  • 1.5 Regulatory-Approved Products

2 Next-Generation Breast Cancer Diagnostic and Screening Market

  • 2.1 Market Outlook
    • 2.1.1 Product Definition
    • 2.1.2 Definition by Technologies Involved
      • 2.1.2.1 Real-Time Polymerase Chain Reaction (RT-PCR)
      • 2.1.2.2 Fluorescence In-Situ Hybridization (FISH)
      • 2.1.2.3 Next-Generation Sequencing
      • 2.1.2.4 Immunohistochemistry (IHC)
    • 2.1.3 Inclusion and Exclusion
    • 2.1.4 Overview
      • 2.1.4.1 Market Size and Growth Potential, $Million, 2022-2032

3 Industry Outlook

  • 3.1 Key Trends
    • 3.1.1 Liquid Biopsy for Breast Cancer Diagnosis
    • 3.1.2 Complete Automation of Next-Generation Techniques
  • 3.2 Regulatory Framework
    • 3.2.1 Regulatory Framework in the U.S.
      • 3.2.1.1 FDA Regulation
      • 3.2.1.2 CMS Regulations (Reimbursement Scenario)
    • 3.2.2 Regulatory Framework in Europe
    • 3.2.3 Regulatory Framework in Asia-Pacific
      • 3.2.3.1 China
      • 3.2.3.2 Japan
  • 3.3 Regulatory-Approved Products
  • 3.4 Clinical Trials
  • 3.5 Breast Cancer Incidence Growth Rates (by Country)
  • 3.6 Advantages and Limitations of Different Techniques
  • 3.7 Pricing

4 Regions

  • 4.1 Asia-Pacific
    • 4.1.1 Key Findings
    • 4.1.2 Market Dynamics
      • 4.1.2.1 Impact Analysis
    • 4.1.3 Market Sizing and Forecast
      • 4.1.3.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
        • 4.1.3.1.1 China
          • 4.1.3.1.1.1 Market Dynamics
          • 4.1.3.1.1.2 Market Sizing and Forecast
        • 4.1.3.1.2 Japan
          • 4.1.3.1.2.1 Market Dynamics
          • 4.1.3.1.2.2 Market Sizing and Forecast
        • 4.1.3.1.3 India
          • 4.1.3.1.3.1 Market Dynamics
          • 4.1.3.1.3.2 Market Sizing and Forecast
        • 4.1.3.1.4 Australia
          • 4.1.3.1.4.1 Market Dynamics
          • 4.1.3.1.4.2 Market Sizing and Forecast
        • 4.1.3.1.5 South Korea
          • 4.1.3.1.5.1 Market Dynamics
          • 4.1.3.1.5.2 Market Sizing and Forecast
        • 4.1.3.1.6 Singapore
          • 4.1.3.1.6.1 Market Dynamics
          • 4.1.3.1.6.2 Market Sizing and Forecast
        • 4.1.3.1.7 Rest-of-Asia-Pacific
          • 4.1.3.1.7.1 Market Dynamics
          • 4.1.3.1.7.2 Market Sizing and Forecast

5 Markets - Competitive Benchmarking

  • 5.1 Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
  • 5.2 Company Profiles
    • 5.2.1 BGI Genomics Co., Ltd.
      • 5.2.1.1 Company Overview
      • 5.2.1.2 Role of BGI Genomics Co., Ltd. in the Next-Generation Breast Cancer Diagnostic and Screening Market
      • 5.2.1.3 Financials
      • 5.2.1.4 Recent Developments
      • 5.2.1.5 Analyst Perception

List of Figures

  • Figure 1: Worldwide Breast Cancer Statistics (by Region), 2020
  • Figure 2: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 3: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Technology), $Million, 2022 and 2032
  • Figure 4: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Biomarker), $Million, 2022 and 2032
  • Figure 5: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Cancer Sub-Type), $Million, 2022 and 2032
  • Figure 6: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Offering), $Million, 2022 and 2032
  • Figure 7: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by End User), $Million, 2022 and 2032
  • Figure 8: Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
  • Figure 9: Next-Generation Breast Cancer Diagnostic and Screening Market, Key Development Analysis, January 2019-April 2023
  • Figure 10: Next-Generation Breast Cancer Diagnostic and Screening Market: Research Methodology
  • Figure 11: Primary Research Methodology
  • Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 13: Top-Down Approach (Segment-Wise Analysis)
  • Figure 14: Oncology Molecular Diagnostic Market, Solid Tumor, $Million, 2022 and 2032
  • Figure 15: Oncology Molecular Diagnostic Market, Hematological Malignancy, $Million, 2022 and 2032
  • Figure 16: Oncology Molecular Diagnostic Market, Market Dynamics
  • Figure 17: Next-Generation Breast Cancer Diagnostic and Screening Market, Size and Growth Potential, $Million, 2022-2032
  • Figure 18: Market Size and Growth Potential (by Region), $Million, 2022-2032
  • Figure 19: FDA Guidelines for CDx Approval
  • Figure 20: Criteria for CMS Coverage/Reimbursement
  • Figure 21: Europe In-Vitro Diagnostic Devices Regulation Regulatory Process
  • Figure 22: Breast Cancer Incidence Growth Rates (by Country), 2020 and 2040
  • Figure 23: Advantages and Limitations of Different Techniques in the Next-Generation Breast Cancer Diagnostic and Screening Market
  • Figure 24: Next-Generation Breast Cancer Diagnostic and Screening Market Share (by Region), 2022-2032
  • Figure 25: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Country), $Million, 2023-2032
  • Figure 26: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 27: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), Share (%), 2022 and 2032
  • Figure 28: China Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 29: Japan Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 30: India Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 31: Australia Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 32: South Korea Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 33: Singapore Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 34: Rest-of-Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 35: BGI Genomics Co., Ltd. Product Portfolio
  • Figure 36: BGI Genomics Co., Ltd.: Overall Financials, $Million, 2020-2022

List of Tables

  • Table 1: Key Questions Answered in the Report
  • Table 2: Some of the Regulatory-Approved Oncology Molecular Diagnostic Products/Services for Different Types of Solid Tumors
  • Table 3: Some of the Regulatory-Approved Next-Generation Breast Cancer Diagnostic and Screening Products/Tests
  • Table 4: Next-Generation Breast Cancer Diagnostic and Screening, Clinical Trials
  • Table 5: Pricing of Some Products/Services for Next-Generation Breast Cancer Diagnostic and Screening
  • Table 6: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
  • Table 7: Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
  • Table 8: BGI Genomics Co. Ltd.: Key Products and Features